FL115 plus PD-1 antibody for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called FL115 combined with an immunotherapy (PD-1 antibody) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have an advanced solid tumor (cancer that has spread) that has either failed other treatments or has no standard treatment options.
- You have at least one tumor that can be measured on a scan.
- You are able to do most of your daily activities on your own (ECOG 0 or 1).
- You have not had certain prior treatments, such as IL-2 or IL-15 therapies, or other cancer treatments within the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of two drugs: peginterferon α-2b (an immune-boosting drug) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). They hope the combo might work better for people with advanced solid tumors that haven't responded to other treatments.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This study tests a new experimental drug called BR113, given as an injection, for people with advanced solid tumor cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective in shrinking or controlling the cancer.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.